Wir heben IT-Weiterbildung auf ein neues Level und bauen interne Technologie-Expertise systematisch auf, sagt Stefan Kiefner ...

Boehringer, Albert Boehringer, hatte 1885 eine chemische Fabrik in Ingelheim am Rhein gegründet ... Patient Care (Pflegeprodukte), Biochemicals und Therapeutics (Pharma-Produkte). 1996 hatte die ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

AMSTERDAM, BASEL, Switzerland and INGELHEIM, Germany, Jan. 9, 2025 /PRNewswire/ -- Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its ...

Under a new licensing pact, Synaffix will grant Boehringer Ingelheim access to its bespoke ADC technologies for an "agreed but undisclosed number of targets." The first target was decided by the ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary ...

Zeit Aktuelle Nachrichten 17.01. Boehringer drug for brain fog in schizophrenia fails trial 16.01. Boehringer's phase 3 schizophrenia program misses primary goal 16.01. Boehringer Ingelheim ...